Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.
AffiliationDepartment of Medical Oncology, Beaumont Hospital, Dublin, Ireland.
MeSHAntibodies, Monoclonal, Humanized
Drug Resistance, Neoplasm
Proto-Oncogene Proteins c-akt
TOR Serine-Threonine Kinases
MetadataShow full item record
CitationOvercoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. 2012, 23 (12):3007-16 Ann. Oncol.
JournalAnnals of oncology : official journal of the European Society for Medical Oncology / ESMO
AbstractApproximately 15%-23% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2), which leads to the activation of signaling pathways that stimulate cell proliferation and survival. HER2-targeted therapy has substantially improved outcomes in patients with HER2-positive breast cancer. However, both de novo and acquired resistance are observed.
The following license files are associated with this item:
- Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
- Authors: Nahta R, O'Regan RM
- Issue date: 2010 Nov
- Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway.
- Authors: Wilks ST
- Issue date: 2015 Oct
- Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
- Authors: O'Brien NA, McDonald K, Tong L, von Euw E, Kalous O, Conklin D, Hurvitz SA, di Tomaso E, Schnell C, Linnartz R, Finn RS, Hirawat S, Slamon DJ
- Issue date: 2014 Jul 1
- Everolimus: a new hope for patients with breast cancer.
- Authors: Sendur MA, Zengin N, Aksoy S, Altundag K
- Issue date: 2014 Jan
- A systematic review of dual targeting in HER2-positive breast cancer.
- Authors: Kümler I, Tuxen MK, Nielsen DL
- Issue date: 2014 Mar